MORF vs. SNDX, ARVN, RDHL, CTLT, QGEN, PCVX, ROIV, LNTH, RVMD, and SMMT
Should you be buying Morphic stock or one of its competitors? The main competitors of Morphic include Syndax Pharmaceuticals (SNDX), Arvinas (ARVN), RedHill Biopharma (RDHL), Catalent (CTLT), Qiagen (QGEN), Vaxcyte (PCVX), Roivant Sciences (ROIV), Lantheus (LNTH), Revolution Medicines (RVMD), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.
Syndax Pharmaceuticals (NASDAQ:SNDX) and Morphic (NASDAQ:MORF) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, community ranking, earnings and institutional ownership.
In the previous week, Morphic had 10 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 14 mentions for Morphic and 4 mentions for Syndax Pharmaceuticals. Morphic's average media sentiment score of 0.58 beat Syndax Pharmaceuticals' score of 0.27 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.
Syndax Pharmaceuticals received 294 more outperform votes than Morphic when rated by MarketBeat users. Likewise, 64.92% of users gave Syndax Pharmaceuticals an outperform vote while only 57.35% of users gave Morphic an outperform vote.
Syndax Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Morphic has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.
Morphic has lower revenue, but higher earnings than Syndax Pharmaceuticals. Morphic is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Syndax Pharmaceuticals currently has a consensus price target of $34.73, suggesting a potential upside of 41.80%. Morphic has a consensus price target of $54.25, suggesting a potential downside of 4.07%. Given Morphic's stronger consensus rating and higher probable upside, equities analysts plainly believe Syndax Pharmaceuticals is more favorable than Morphic.
Syndax Pharmaceuticals' return on equity of -22.93% beat Morphic's return on equity.
94.3% of Morphic shares are owned by institutional investors. 4.1% of Syndax Pharmaceuticals shares are owned by insiders. Comparatively, 25.6% of Morphic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Syndax Pharmaceuticals beats Morphic on 9 of the 17 factors compared between the two stocks.
Get Morphic News Delivered to You Automatically
Sign up to receive the latest news and ratings for MORF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MORF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
